Roche IL-6R Antibody Satralizumab Receives FDA Approval for Thyroid Eye Disease

Roche announced that the FDA has approved a supplemental Biologics License Application for Enspryng (satralizumab), an IL-6R monoclonal antibody, in adults with thyroid eye disease (TED). According to the source, it is a TED therapy that patients or trained caregivers can self-administer by subcutaneous injection at home, and it was developed by Chugai Pharmaceutical, part of Roche.